search
Back to results

Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer

Primary Purpose

Colorectal Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
curative proton therapy
Sponsored by
National Cancer Center, Korea
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Cancer focused on measuring Lung Metastasis, Curative Proton Beam Therapy

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Histologically diagnosed colon adenocarcinoma in primary or metastatic lesions..
  2. If there is no other remote metastasis other than lung, or if there is, control is possible
  3. If there are less than 2 lung metastatic lesions
  4. If they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.)

Exclusion Criteria:

  1. Other histologic cancer other than adenocarcinoma of the colorectal
  2. Colorectal cancer without primary lesion resection
  3. If there is another remote metastasis and is not completely resected or regulated
  4. If the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis
  5. Pregnancy and women under lactation

Sites / Locations

  • National Cancer Center KoreaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

curative proton therapy

Arm Description

Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks

Outcomes

Primary Outcome Measures

3-year local control ratio of the treated lung area
The primary goal of this study is the 3-year local control rate of pulmonary lesions treated with proton therapy. It is judged that the local control rate is improved when the pulmonary metastases of colorectal cancer using conventional X-ray is assumed to have 3-year local control rate of 60% and the 3-year local control rate of proton therapy is set to 80% or more

Secondary Outcome Measures

3-year survival rate of treated patients
To evaluate whether high doses of proton therapy can replace conventional surgical resection. From date of initiation of proton therapy until the date of documented date of death from any cause, assessed up to 3 years
3-year disease-free survival rate of treated patients
To evaluate whether high doses of proton therapy can replace conventional surgical resection. From date of initiation of proton therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.

Full Information

First Posted
June 11, 2018
Last Updated
August 19, 2019
Sponsor
National Cancer Center, Korea
search

1. Study Identification

Unique Protocol Identification Number
NCT03566355
Brief Title
Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
Official Title
A Phase II Study of Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Recruiting
Study Start Date
May 23, 2018 (Actual)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Cancer Center, Korea

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total
Detailed Description
This clinical trial is a prospective, single-organ, phase II clinical trial to evaluate the efficacy of curative proton therapy for pulmonary metastasis of colon cancer diagnosed histologically as adenocarcinoma. Patients who meet the selection criteria should be selected, signed for consent, and treated 5 times a week for 7200 cGy / 15 fractions alone for 3 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer
Keywords
Lung Metastasis, Curative Proton Beam Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
36 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
curative proton therapy
Arm Type
Experimental
Arm Description
Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
Intervention Type
Radiation
Intervention Name(s)
curative proton therapy
Intervention Description
Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
Primary Outcome Measure Information:
Title
3-year local control ratio of the treated lung area
Description
The primary goal of this study is the 3-year local control rate of pulmonary lesions treated with proton therapy. It is judged that the local control rate is improved when the pulmonary metastases of colorectal cancer using conventional X-ray is assumed to have 3-year local control rate of 60% and the 3-year local control rate of proton therapy is set to 80% or more
Time Frame
up to 3 years
Secondary Outcome Measure Information:
Title
3-year survival rate of treated patients
Description
To evaluate whether high doses of proton therapy can replace conventional surgical resection. From date of initiation of proton therapy until the date of documented date of death from any cause, assessed up to 3 years
Time Frame
documented data of death, up to 3 years
Title
3-year disease-free survival rate of treated patients
Description
To evaluate whether high doses of proton therapy can replace conventional surgical resection. From date of initiation of proton therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.
Time Frame
documented date of progression or death, up to 3 years

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically diagnosed colon adenocarcinoma in primary or metastatic lesions.. If there is no other remote metastasis other than lung, or if there is, control is possible If there are less than 2 lung metastatic lesions If they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.) Exclusion Criteria: Other histologic cancer other than adenocarcinoma of the colorectal Colorectal cancer without primary lesion resection If there is another remote metastasis and is not completely resected or regulated If the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis Pregnancy and women under lactation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dae Yong Kim, M.D.
Phone
82-31-920-1721
Email
radiopia@ncc.re.kr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dae Yong Kim, M.D.
Organizational Affiliation
National Cancer Center Korea(South Korea)
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Cancer Center Korea
City
Goyang-si
State/Province
Gyeonggi-do
ZIP/Postal Code
10406
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dae Yong Kim, M.D.
Phone
82-31-920-1721
Email
radiopia@ncc.re.kr

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer

We'll reach out to this number within 24 hrs